Clinical Cancer Research Targets Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karamouzis, M. V.
Right arrow Articles by Papavassiliou, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karamouzis, M. V.
Right arrow Articles by Papavassiliou, A. G.
Clinical Cancer Research Vol. 8, 949-961, May 2002
© 2002 American Association for Cancer Research


Review

Transcription Factors and Neoplasia

Vistas in Novel Drug Design

Mihalis V. Karamouzis, Vassilis G. Gorgoulis and Athanasios G. Papavassiliou1

Department of Biochemistry, School of Medicine, University of Patras, GR-26110 Patras [M. V. K., A. G. P.], and Department of Histology and Embryology, School of Medicine, University of Athens, GR-11527 Athens [V. G. G.], Greece

Purpose: The fundamental role of gene transcription and the recognition of transcription factors as important control elements of cell growth, differentiation, and programmed cell death (apoptosis) aroused an ever-increasing interest for these proteins as potential pharmaceutical targets for therapeutic intervention in various diseases, among them cancer.

Experimental Design–Results: The vast array of information available for their molecular architecture and mode of action in various biological contexts, combined with the new opportunities offered by the flourishing technologies of structure-based drug design, computer-aided modeling, and functional genomics/proteomics, are creating an exciting scenery for the development of a novel generation of highly selective drugs.

Conclusions: This transcription factor-based therapeutic approach may revolutionize the anticancer drug options and will add significantly to the current clinical armamentarium.




This article has been cited by other articles:


Home page
Cancer Res.Home page
R. Amstutz, M. Wachtel, H. Troxler, P. Kleinert, M. Ebauer, T. Haneke, C. Oehler-Janne, D. Fabbro, F. K. Niggli, and B. W. Schafer
Phosphorylation Regulates Transcriptional Activity of PAX3/FKHR and Reveals Novel Therapeutic Possibilities
Cancer Res., May 15, 2008; 68(10): 3767 - 3776.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
M. V. Karamouzis, P. A. Konstantinopoulos, and A. G. Papavassiliou
The Activator Protein-1 Transcription Factor in Respiratory Epithelium Carcinogenesis
Mol. Cancer Res., February 1, 2007; 5(2): 109 - 120.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.